Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers.
The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare.
Anlon Healthcare is pursuing a sizeable inorganic and organic expansion plan: management completed the Apiqo Organics deal, is proposing Bizotic Life Science acquisition, and announced greenfield/organic expansions with planned capital expenditure of about INR 100–120 crore to materially increase installed capacity and support projected revenue growth for Anlon Healthcare.
The company emphasises regulatory and product pipeline progress: management has 21 DMFs filed, expects commercialisation of several DMF products next year, is developing three CDMO molecules for global innovators with validations underway, and targets broader regulated‑market penetration and new API launches to diversify Anlon Healthcare's therapeutic exposure and margin profile.
Pharmaceuticals & Biotechnology
Pharmaceuticals
796 Cr
Low Risk
28.6
34.1
0.2
3.5
17.20
8.70
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Anlon Healthcare Ltd (AHCL) is currently trading at 15.08 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Anlon Healthcare manufactures pharmaceutical APIs and high‑purity intermediates from its Rajkot facility, provides custom manufacturing (CDMO) services, and has expanded via an IPO in August 2025; the company reports regulatory filings including 21 DMFs and commercial presence across 15 countries, positioning Anlon Healthcare as a research-driven API/intermediate manufacturer focused on regulated market customers. The company reported a sharp year‑on‑year operational improvement: Q3 total income rose to INR 35.78 crore from INR 9.38 crore a year earlier, EBITDA of INR 12.54 crore at 35.1% margin and a return to PAT of INR 5.15 crore, reflecting stronger product mix, operating leverage and an expanding CDMO pipeline for Anlon Healthcare. Anlon Healthcare is pursuing a sizeable inorganic and organic expansion plan: management completed the Apiqo Organics deal, is proposing Bizotic Life Science acquisition, and announced greenfield/organic expansions with planned capital expenditure of about INR 100–120 crore to materially increase installed capacity and support projected revenue growth for Anlon Healthcare. The company emphasises regulatory and product pipeline progress: management has 21 DMFs filed, expects commercialisation of several DMF products next year, is developing three CDMO molecules for global innovators with validations underway, and targets broader regulated‑market penetration and new API launches to diversify Anlon Healthcare's therapeutic exposure and margin profile.
Over the past 52 weeks, Anlon Healthcare Ltd has traded between a low of ₹8.70 and a high of ₹17.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Anlon Healthcare Ltd has a market capitalization of approximately 796.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Anlon Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.63 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 796.21 Cr, Anlon Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Anlon Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Anlon Healthcare Ltd is 28.63. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
11
Bullish
32
Bearish
0
Neutral
4
Bullish
28
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
273.00 | 895 Cr | 20.81 | 11.55 | 0.00 | 51.51 | 27.98 | 10.39 | ||
183.75 | 850 Cr | 33.03 | 1.60 | 1.70 | 4.85 | 6.56 | 2.83 | ||
696.35 | 805 Cr | 21.75 | 2.29 | 0.07 | 10.54 | 16.04 | 7.98 | ||
15.08 | 796 Cr | 28.63 | 3.46 | 0.00 | 12.38 | 16.89 | — | ||
20.94 | 783 Cr | -9.58 | 1.50 | 0.49 | 6.52 | 6.49 | -9.84 | ||
599.95 | 761 Cr | 42.82 | 4.67 | 0.00 | 10.90 | 14.23 | 8.56 | ||
79.52 | 760 Cr | 18.52 | 2.16 | 1.98 | 11.65 | 15.53 | 7.36 | ||
| Median: 7 Co. | — | 183.75 | 796 Cr | 21.75 | 2.29 | 0.07 | 10.90 | 15.53 | 7.67 |
Earnings Call Transcript
Anlon released the Q4 & FY26 earnings call transcript: FY26 revenue INR172.22cr (+42.98% YoY), EBITDA INR47.77cr, PAT INR29.09cr; Q4 income INR50.90cr; capacity ~62% utilization; acquisitions (Apiqo, Bizotic); FY27 guidance INR380–400cr; capex INR130cr.
Earnings Call Transcript
Anlon released the Q4 & FY26 earnings call transcript: FY26 revenue INR 172.22cr (+42.98%), EBITDA INR 47.77cr (+47.55%), PAT INR 29.09cr (+41.77%); capacity ~1,400–1,600 tpa, acquisitions done, FY27 revenue guidance INR 380–400cr and ~30% CAGR target.
